New Leaf Venture

Truveris, Inc. is a health information technology company based in New York that focuses on the management of pharmacy benefits and prescription drug costs. Founded in 2009, the company offers a comprehensive platform that includes solutions such as RxChoice, TruBid, and RxDash, which cater to various stakeholders in the prescription drug ecosystem, including pharmaceutical manufacturers, pharmacy benefit managers, and payers. Truveris leverages data-driven innovations to provide actionable insights that help clients navigate the complexities of pharmacy spending, ensure regulatory compliance, and validate claim payment accuracy. By offering tools for managing the entire pharmacy benefits lifecycle—from request for proposal to bill review—Truveris aims to enhance transparency and efficiency in the prescription drug market. The company's backing from multiple venture capital firms underscores its commitment to addressing rising costs and improving access to prescription medications.

Qlaris Bio, Inc. is a clinical-stage biotechnology company based in Wellesley, Massachusetts, focused on developing innovative therapies for serious ophthalmic diseases. Founded in 2017, the company is working on QLS-101, a therapy aimed at reducing intraocular pressure, a critical factor in conditions such as glaucoma. Qlaris Bio explores novel mechanisms to address episcleral venous pressure, which significantly contributes to intraocular pressure, thereby aiming to mitigate the risk of blindness associated with both Primary Open Angle Glaucoma and Normal Tension Glaucoma. The company also targets high unmet medical needs in pediatric rare diseases related to intraocular pressure disturbances, where effective treatment options are currently limited.

Flosonics Medical is a medical device company based in Sudbury, Canada, founded in 2017. It specializes in the development of non-invasive sensors aimed at enhancing the management of critically ill patients. The company's flagship product, the FloPatch, is a wearable sensor designed to monitor blood flow in patients' necks following clinical interventions. This innovative device addresses critical clinical needs for healthcare professionals, including physicians, nurses, and paramedics, working in various settings such as ambulances, emergency departments, operating rooms, and intensive care units. By integrating wearable ultrasound technology with connected devices, Flosonics Medical provides portable and user-friendly solutions that facilitate hands-free operation and improve patient care.

Harpoon Therapeutics is a clinical-stage immunotherapy company focused on developing innovative T cell engagers to harness the body's immune system for treating cancer and other diseases. Utilizing its proprietary TriTAC platform, the company is working on a pipeline of engineered proteins designed to direct T cells to target and eliminate specific cancer cells. The lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, Harpoon is developing HPN536, which is in Phase I/IIa trials for ovarian cancer and other tumors expressing MSLN, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Founded in 2015 and headquartered in South San Francisco, California, Harpoon Therapeutics has established a collaboration agreement with AbbVie Biotechnology Ltd to further its research efforts.

Arvist specializes in enhancing warehouse and distribution center operations through real-time digital twin technology. By leveraging existing data and security camera footage, the company minimizes supply chain disruptions and reduces costs without the need for additional infrastructure investments. Arvist's innovative approach combines unique marker technology with artificial intelligence, enabling businesses to gain critical visibility into their operations. This empowers organizations to achieve greater efficiency, productivity, and safety, ultimately transforming warehouses into smarter, more responsive environments.

Star Therapeutics is a biotechnology company focused on developing innovative therapies for a wide range of rare diseases. The company aims to identify diseases that share common biological characteristics and create novel therapeutics that can effectively treat multiple conditions with a single treatment. This approach not only addresses the needs of patients suffering from rare diseases but also presents a unique opportunity for pharmaceutical companies to broaden their therapeutic offerings within a streamlined pipeline. By concentrating on life-changing therapies, Star Therapeutics aspires to make a significant impact on the lives of millions of patients.

Harpoon Therapeutics is a clinical-stage immunotherapy company focused on developing innovative T cell engagers to harness the body's immune system for treating cancer and other diseases. Utilizing its proprietary TriTAC platform, the company is working on a pipeline of engineered proteins designed to direct T cells to target and eliminate specific cancer cells. The lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, Harpoon is developing HPN536, which is in Phase I/IIa trials for ovarian cancer and other tumors expressing MSLN, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Founded in 2015 and headquartered in South San Francisco, California, Harpoon Therapeutics has established a collaboration agreement with AbbVie Biotechnology Ltd to further its research efforts.

Arine Inc. is a San Francisco-based company that develops a medication management platform aimed at improving patient health and quality of life. Founded in 2017, Arine utilizes a clinical learning and analytic response engine to deliver data-driven clinical services. The platform aggregates and analyzes clinical, social, and behavioral data to identify and address gaps in patient care, providing tailored medication recommendations and education to patients and their care teams. By focusing on evidence-based approaches, Arine optimizes medication use, enhances patient outcomes, and aims to reduce the overall cost of care. Their commitment to continuous monitoring and evaluation ensures timely follow-up and meaningful clinical service programs, guiding patients throughout their healthcare journey.

Star Therapeutics is a biotechnology company focused on developing innovative therapies for a wide range of rare diseases. The company aims to identify diseases that share common biological characteristics and create novel therapeutics that can effectively treat multiple conditions with a single treatment. This approach not only addresses the needs of patients suffering from rare diseases but also presents a unique opportunity for pharmaceutical companies to broaden their therapeutic offerings within a streamlined pipeline. By concentrating on life-changing therapies, Star Therapeutics aspires to make a significant impact on the lives of millions of patients.

Electra Therapeutics is a clinical-stage biotechnology company focused on developing therapies that target signal regulatory proteins (SIRP) for treating immunological diseases and cancer. The company has one program in clinical development and two additional preclinical programs. Its lead product candidate, ELA026, is a monoclonal antibody designed to target SIRP on the surface of myeloid and T cells, effectively depleting pathological immune cells. ELA026 is currently being investigated for secondary hemophagocytic lymphohistiocytosis (sHLH), a severe hyperinflammatory condition for which no approved treatment exists.

Asimily, Inc. is a technology company that specializes in securing healthcare devices through its innovative risk remediation platform. Founded in 2017 and based in Sunnyvale, California, Asimily offers a healthcare-specific management platform that utilizes distributed analytics to monitor and manage both connected and standalone medical devices. The platform provides a comprehensive inventory and classification of devices, identifying and prioritizing vulnerabilities while delivering actionable insights for effective remediation. By leveraging big data and machine learning, Asimily ensures that healthcare organizations can continuously assess risks and detect anomalies in device behavior. This proactive approach helps to safeguard resources, enhance patient safety, and protect IT assets within healthcare settings.

DICE Therapeutics is a biopharmaceutical company that utilizes its proprietary technology platform to develop a pipeline of novel oral therapeutic candidates aimed at treating chronic diseases, particularly in the field of immunology. The company focuses on creating oral therapeutics that target well-established proteins, intending to achieve efficacy similar to existing systemic biologics. DICE's DELSCAPE platform is specifically designed to discover selective oral small molecules capable of modulating protein-protein interactions effectively. Its lead candidate, S011806, is an oral antagonist targeting interleukin-17, a key player in various immunological conditions. In addition to S011806, DICE is developing other oral therapeutic candidates that target α4ß7 integrin and αVß1/αVß6 integrin, aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

Cleerly is a healthcare company focused on improving the prevention of heart attacks through innovative digital care pathways. It aims to establish a new standard for coronary artery disease by combining advanced clinical science with cutting-edge artificial intelligence. Cleerly's platform offers a non-invasive approach that quantifies and characterizes plaque buildup in coronary arteries, enhancing the understanding of cardiovascular health. By providing actionable clinical insights, the company enables healthcare providers to better identify at-risk patients and implement early treatment strategies. Ultimately, Cleerly's data-driven solutions aspire to deliver significant value to the healthcare system while improving heart health outcomes for individuals susceptible to heart attacks.

Akili Interactive is a digital medicine company focused on developing innovative cognitive treatments using technology. The company has a diverse pipeline of programs designed to address cognitive deficiencies and alleviate symptoms associated with various medical conditions. These include attention-deficit hyperactivity disorder (ADHD), major depressive disorder (MDD), autism spectrum disorder (ASD), and several inflammatory diseases. By leveraging engaging digital platforms, Akili aims to improve patient outcomes in the fields of neurology and psychiatry through its unique therapeutic approaches.

BrightInsight operates a digital health platform tailored for biopharma and medtech companies, focusing on the development and optimization of regulated drugs, devices, and software. Founded in 2017 and headquartered in San Jose, California, the company offers a global regulated platform that utilizes Internet of Things (IoT) technology. This platform facilitates the capture, transmission, and analysis of data from connected medical devices, combination products, and digital therapeutics. By adhering to rigorous security, privacy, and regulatory standards, BrightInsight enables its clients to enhance patient adherence and engagement, streamline their processes, and accelerate time to market while reducing implementation costs. With an additional office in Hägglingen, Switzerland, BrightInsight is positioned to support customers in navigating the complexities of the digital health landscape.

DICE Therapeutics is a biopharmaceutical company that utilizes its proprietary technology platform to develop a pipeline of novel oral therapeutic candidates aimed at treating chronic diseases, particularly in the field of immunology. The company focuses on creating oral therapeutics that target well-established proteins, intending to achieve efficacy similar to existing systemic biologics. DICE's DELSCAPE platform is specifically designed to discover selective oral small molecules capable of modulating protein-protein interactions effectively. Its lead candidate, S011806, is an oral antagonist targeting interleukin-17, a key player in various immunological conditions. In addition to S011806, DICE is developing other oral therapeutic candidates that target α4ß7 integrin and αVß1/αVß6 integrin, aimed at treating inflammatory bowel disease and idiopathic pulmonary fibrosis, respectively.

TigerConnect is a provider of clinical communication solutions tailored for the healthcare sector, enabling effective collaboration among doctors, nurses, patients, and care providers. Founded in 2010 and headquartered in Santa Monica, California, the company offers a platform that integrates real-time mobile messaging with a user-friendly interface, while prioritizing security and privacy. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. Its innovative products and seamless integrations with essential hospital systems enhance workflow efficiency, ultimately accelerating productivity, reducing costs, and improving patient outcomes. The company's commitment to client success is evident through its dedicated support organization, which collaborates with clients to optimize communication workflows and maximize return on investment.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.

Saniona is a pharmaceutical company dedicated to researching and developing innovative treatments for various diseases, including those affecting the central nervous system, autoimmune disorders, metabolic conditions, and pain management. The company specializes in the development of highly selective ion channel modulators, employing a technology platform that targets GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. Its most advanced product candidate, Tesomet, is currently in mid-stage clinical trials for rare eating disorders. Additionally, Saniona is advancing two other product candidates: SAN711, which has successfully completed a Phase 1 clinical trial for neuropathic pain conditions, and SAN903, which is preparing to enter Phase 1 trials for inflammatory and fibrotic disorders. The company is committed to leveraging its expertise in ion channel modulation to create effective new medicines.

Glympse Bio, Inc. is a diagnostic company based in Cambridge, Massachusetts, that focuses on developing modular nanoparticle sensors for noninvasive disease monitoring. Founded in 2015, the company creates engineered diagnostic agents designed to interrogate the body for specific disease states, subsequently conveying this information through urine analysis. This innovative approach facilitates the monitoring of various conditions, including fibrosis, cancer, immunology, and infectious diseases, while also assessing drug responses. Glympse Bio's flagship product, Glympse Inside, serves as a pan-disease platform aimed at revolutionizing how diseases are monitored and treated. The technology was initially developed at MIT and is supported by a team of experts in nanomedicine and biomedical engineering.

BrightInsight operates a digital health platform tailored for biopharma and medtech companies, focusing on the development and optimization of regulated drugs, devices, and software. Founded in 2017 and headquartered in San Jose, California, the company offers a global regulated platform that utilizes Internet of Things (IoT) technology. This platform facilitates the capture, transmission, and analysis of data from connected medical devices, combination products, and digital therapeutics. By adhering to rigorous security, privacy, and regulatory standards, BrightInsight enables its clients to enhance patient adherence and engagement, streamline their processes, and accelerate time to market while reducing implementation costs. With an additional office in Hägglingen, Switzerland, BrightInsight is positioned to support customers in navigating the complexities of the digital health landscape.

Rallybio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with severe and rare disorders. Founded in 2018 and based in New Haven, Connecticut, the company is advancing its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition that can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's portfolio includes a range of promising product candidates targeting rare diseases across various therapeutic areas, including hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. The company's efforts are supported by a team of experienced professionals with extensive expertise in biopharma research and development.

AiCure, LLC is a technology company that specializes in medication adherence and intelligent medical assistant solutions, utilizing a visual recognition platform to monitor patient progress via mobile devices. The company's software confirms medication ingestion, particularly in clinical trials and high-risk populations, by identifying both patients and medications while detecting issues such as diversion and duplicate enrollments. It captures evidence of medication ingestion for immediate intervention and long-term adherence tracking. AiCure's platform incorporates advanced data analytics, including patented facial recognition and motion-sensing technology, to link patient behavior with treatment outcomes. This innovative approach aims to enhance healthcare delivery systems by improving treatment efficacy and reducing risks. Founded in 2009 and based in New York, AiCure has established a strategic partnership with Syneos Health to further advance its solutions.

Edgewise Therapeutics is a clinical-stage biopharmaceutical company based in Boulder, Colorado, that specializes in developing small molecule therapies for severe, rare musculoskeletal diseases. Founded in 2017, the company employs a precision medicine approach to create innovative treatments targeting various muscle disorders, including Duchenne and Becker muscular dystrophies, as well as limb girdle muscular dystrophies. Utilizing its proprietary muscle-focused drug discovery platform, Edgewise integrates expertise in muscle biology and small molecule engineering to identify and develop therapies that address genetically defined muscle disorders. The company emphasizes a holistic drug discovery method that assesses integrated muscle function, enabling it to create orally bioavailable therapies aimed at improving outcomes for patients with significant unmet medical needs in neuromuscular and cardiac diseases.

BrightInsight operates a digital health platform tailored for biopharma and medtech companies, focusing on the development and optimization of regulated drugs, devices, and software. Founded in 2017 and headquartered in San Jose, California, the company offers a global regulated platform that utilizes Internet of Things (IoT) technology. This platform facilitates the capture, transmission, and analysis of data from connected medical devices, combination products, and digital therapeutics. By adhering to rigorous security, privacy, and regulatory standards, BrightInsight enables its clients to enhance patient adherence and engagement, streamline their processes, and accelerate time to market while reducing implementation costs. With an additional office in Hägglingen, Switzerland, BrightInsight is positioned to support customers in navigating the complexities of the digital health landscape.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Qlaris Bio, Inc. is a clinical-stage biotechnology company based in Wellesley, Massachusetts, focused on developing innovative therapies for serious ophthalmic diseases. Founded in 2017, the company is working on QLS-101, a therapy aimed at reducing intraocular pressure, a critical factor in conditions such as glaucoma. Qlaris Bio explores novel mechanisms to address episcleral venous pressure, which significantly contributes to intraocular pressure, thereby aiming to mitigate the risk of blindness associated with both Primary Open Angle Glaucoma and Normal Tension Glaucoma. The company also targets high unmet medical needs in pediatric rare diseases related to intraocular pressure disturbances, where effective treatment options are currently limited.

Renovacor, Inc. is a preclinical-stage biopharmaceutical company based in Philadelphia, Pennsylvania, dedicated to developing gene therapies for cardiovascular diseases. Founded in 2013, the company focuses on innovative treatments for dilated cardiomyopathy (DCM), particularly cases caused by mutations in the BAG3 gene. This condition affects over 3 million individuals in the United States, with around 35,000 patients estimated to have BAG3 mutations, classifying it as an orphan disease. Patients with BAG3-associated DCM, often younger and experiencing faster disease progression, currently have limited treatment options, primarily consisting of standard heart failure care. Renovacor's lead program involves a recombinant adeno-associated virus (AAV)-based gene therapy aimed at replacing the defective BAG3 gene, which holds the potential to prevent disease progression and improve outcomes for this vulnerable patient population.

Passage Bio is a genetic medicines company based in Philadelphia, Pennsylvania, specializing in the development of therapies for rare monogenic central nervous system (CNS) diseases. Founded in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics, targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while managing clinical development, regulatory affairs, manufacturing, and commercialization of its product candidates. The company also engages with the Orphan Disease Center for natural history studies, key opinion leader involvement, and patient advocacy.

Bellus Health is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare diseases, with a particular focus on conditions affecting the kidneys. Its lead drug candidate, KIACTA™, is designed for the treatment of AA amyloidosis, a rare condition that can result in severe renal dysfunction. Following the successful completion of a Phase 3 study, the company is collaborating with Auven Therapeutics to advance KIACTA™, which is also being explored for treating sarcoidosis, an inflammatory disease affecting the lungs. Additionally, Bellus Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome, a serious condition linked to Shiga toxin-producing E. coli, which poses significant health risks, especially for children. The company's research pipeline also includes efforts to address AL amyloidosis, another rare disease characterized by the accumulation of amyloid proteins in the body. Bellus Health aims to meet the high unmet medical needs of patients suffering from these conditions through its focused therapeutic developments.

Harpoon Therapeutics is a clinical-stage immunotherapy company focused on developing innovative T cell engagers to harness the body's immune system for treating cancer and other diseases. Utilizing its proprietary TriTAC platform, the company is working on a pipeline of engineered proteins designed to direct T cells to target and eliminate specific cancer cells. The lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, Harpoon is developing HPN536, which is in Phase I/IIa trials for ovarian cancer and other tumors expressing MSLN, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Founded in 2015 and headquartered in South San Francisco, California, Harpoon Therapeutics has established a collaboration agreement with AbbVie Biotechnology Ltd to further its research efforts.

CuraSen Therapeutics Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company specializes in small molecule drugs that target a novel mechanism in the brain, aiming to restore function, improve symptoms, and modify the progression of conditions such as Parkinson's disease, Alzheimer's disease, and less common orphan neurodegenerative disorders. Founded in 2016, CuraSen Therapeutics is headquartered in Los Altos, California.

ReViral Ltd is a biotechnology company based in Stevenage, United Kingdom, that specializes in the discovery and development of antiviral drugs targeting the respiratory syncytial virus (RSV). Founded in 2011, ReViral focuses on creating novel first-in-class compounds, including a highly potent fusion inhibitor designed to treat severe RSV infections, particularly in vulnerable populations such as neonates. The company's innovative approach aims to expand the antiviral market by providing effective treatment options for patients affected by RSV, a virus known for causing significant respiratory illness. Through its research and development efforts, ReViral seeks to address unmet medical needs in the realm of viral infections.

Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia. Founded in 2013 and headquartered in South San Francisco, California, the company utilizes advanced antibody technology and insights from neuroimmunology and human genetics to create innovative treatments. Alector’s pipeline includes several candidates, such as AL001, which is undergoing phase II clinical trials for frontotemporal dementia, and AL101, currently in phase I trials for Alzheimer's and Parkinson's diseases. Additionally, AL002 and AL003 are in phase 1b trials for Alzheimer’s disease. The company is actively engaged in research and development, with a total of ten programs at various stages. Alector has formed a strategic collaboration with Adimab, LLC to enhance its antibody research and development capabilities, aiming to efficiently generate and validate antibody drugs that target key disease-related mechanisms.

IRLAB Therapeutics AB is a Swedish research and development company focused on creating innovative treatments for neurological disorders, particularly Parkinson’s disease. The company is advancing several drug candidates, including Mesdopetam, a dopamine D3 receptor antagonist, and IRL752, which targets postural dysfunction. Both compounds have successfully completed Phase IIa clinical trials. Additionally, IRLAB is exploring other research programs aimed at addressing neurodegenerative disorders and aging, such as IRL942, P001, and P003, which seeks alternatives to levodopa for Parkinson’s treatment. By focusing on the core dysfunctions associated with Parkinson’s disease and dementias, IRLAB aims to enhance the quality of life for patients suffering from these conditions. The company is headquartered in Gothenburg, Sweden.

Neurana Pharmaceuticals, Inc. is a pharmaceutical company based in San Diego, California, focusing on the development of treatments for neuromuscular conditions. Founded in 2013, the company specializes in a novel therapeutic compound, Tolperisone, which addresses acute and painful muscle spasms in the neck and back as well as other musculoskeletal issues. Unlike traditional muscle relaxants, Tolperisone provides relief without causing sedation, offering a unique solution for patients experiencing spasticity and muscle discomfort.

Rallybio is a clinical-stage biopharmaceutical company focused on developing transformative therapies for patients with severe and rare disorders. Founded in 2018 and based in New Haven, Connecticut, the company is advancing its lead product candidate, RLYB211, which aims to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a serious condition that can lead to uncontrolled bleeding in fetuses and newborns. Rallybio's portfolio includes a range of promising product candidates targeting rare diseases across various therapeutic areas, including hematology, immuno-inflammation, maternal-fetal health, and metabolic disorders. The company's efforts are supported by a team of experienced professionals with extensive expertise in biopharma research and development.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Technology Will Save Us Ltd. is a London-based company that develops DIY gadget kits and hardware, designed to engage families, educators, and young people in technology-based learning. Founded in 2011, the company offers a variety of products, including a handheld games console, an electronic synthesizer, conductive dough, and moisture sensors, which aim to inspire creativity and innovation. Their award-winning make-it-yourself kits and digital tools facilitate hands-on experiences that encourage children and their parents to explore coding and invention. Technology Will Save Us serves a global audience, reaching over 87 countries through online sales and kiosks in the United Kingdom. The company emphasizes collaboration with children in the design process, ensuring that their products are both educational and enjoyable. With a dedicated team of designers, educators, and engineers, the company is committed to empowering young people to become creators of technology.

Braeburn Inc. is a pharmaceutical company focused on developing and commercializing treatments for serious central nervous system disorders, with a primary emphasis on opioid addiction. Founded in 2012 and headquartered in Plymouth Meeting, Pennsylvania, Braeburn aims to provide innovative solutions for individuals affected by opioid use disorder (OUD). The company's lead product candidate, BRIXADI, is an extended-release injectable formulation of buprenorphine designed for the treatment of moderate to severe OUD. Braeburn is committed to advancing next-generation therapies that offer individualized dosing regimens and delivery options, striving to improve care for patients and address the growing challenges associated with addiction.

Aptinyx Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for brain and nervous system disorders. Founded in 2015 and based in Evanston, Illinois, the company focuses on novel, synthetic small molecules that modulate the NMDA receptor, enhancing communication pathways between nerve cells. Its primary products in development include NYX-2925, which is undergoing Phase II trials for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, Aptinyx is developing NYX-458, another NMDA receptor modulator, which is in Phase I clinical studies aimed at treating cognitive impairment associated with Parkinson’s disease. The company also collaborates with Allergan to develop compounds for major depressive disorder, underscoring its commitment to addressing significant unmet medical needs in the central nervous system arena.

AiCure, LLC is a technology company that specializes in medication adherence and intelligent medical assistant solutions, utilizing a visual recognition platform to monitor patient progress via mobile devices. The company's software confirms medication ingestion, particularly in clinical trials and high-risk populations, by identifying both patients and medications while detecting issues such as diversion and duplicate enrollments. It captures evidence of medication ingestion for immediate intervention and long-term adherence tracking. AiCure's platform incorporates advanced data analytics, including patented facial recognition and motion-sensing technology, to link patient behavior with treatment outcomes. This innovative approach aims to enhance healthcare delivery systems by improving treatment efficacy and reducing risks. Founded in 2009 and based in New York, AiCure has established a strategic partnership with Syneos Health to further advance its solutions.

ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions such as endometriosis, heavy menstrual bleeding, and preterm labor. Its key products include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and uterine fibroids, and OBE022, a selective prostaglandin F2α receptor antagonist designed for once-daily treatment of preterm labor. Additionally, ObsEva is advancing Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily in Switzerland and is committed to improving outcomes for women facing reproductive health challenges.

Truveris, Inc. is a health information technology company based in New York that focuses on the management of pharmacy benefits and prescription drug costs. Founded in 2009, the company offers a comprehensive platform that includes solutions such as RxChoice, TruBid, and RxDash, which cater to various stakeholders in the prescription drug ecosystem, including pharmaceutical manufacturers, pharmacy benefit managers, and payers. Truveris leverages data-driven innovations to provide actionable insights that help clients navigate the complexities of pharmacy spending, ensure regulatory compliance, and validate claim payment accuracy. By offering tools for managing the entire pharmacy benefits lifecycle—from request for proposal to bill review—Truveris aims to enhance transparency and efficiency in the prescription drug market. The company's backing from multiple venture capital firms underscores its commitment to addressing rising costs and improving access to prescription medications.

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing innovative treatments for cancer. The company aims to improve the lives of cancer patients by addressing mechanisms of drug resistance that hinder effective therapy responses. Its lead candidate, ripretinib, is specifically designed for gastrointestinal stromal tumors and is undergoing trials for various other cancers, including gliomas and melanoma. Additionally, Deciphera is advancing other clinical-stage candidates, such as DCC-3014, targeting tenosynovial giant cell tumors, and Rebastinib, which is being explored in combination with chemotherapy for solid tumors. The company also has a preclinical candidate, DCC-3116, aimed at treating RAS mutant cancers. Deciphera leverages its proprietary switch-control kinase inhibitor platform and has received regulatory approvals for its lead product in several countries, enhancing its commitment to developing vital cancer therapies.

Harpoon Therapeutics is a clinical-stage immunotherapy company focused on developing innovative T cell engagers to harness the body's immune system for treating cancer and other diseases. Utilizing its proprietary TriTAC platform, the company is working on a pipeline of engineered proteins designed to direct T cells to target and eliminate specific cancer cells. The lead product candidate, HPN424, is currently undergoing Phase I clinical trials for metastatic castration-resistant prostate cancer. Additionally, Harpoon is developing HPN536, which is in Phase I/IIa trials for ovarian cancer and other tumors expressing MSLN, as well as HPN217 for multiple myeloma and HPN328 for small cell lung cancer. Founded in 2015 and headquartered in South San Francisco, California, Harpoon Therapeutics has established a collaboration agreement with AbbVie Biotechnology Ltd to further its research efforts.

Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing anti-infective therapies to address multi-drug resistant pathogens. Headquartered in Dublin, Ireland, the company is advancing its lead product, sulopenem, a novel penem compound available in both oral and intravenous formulations. Currently in Phase III clinical trials, sulopenem is being evaluated for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum aims to provide effective solutions to combat antibiotic resistance, particularly against a range of gram-negative, gram-positive, and anaerobic bacteria that are resistant to existing antibiotics. Founded in 2015, Iterum Therapeutics seeks to improve the lives of patients affected by serious and life-threatening infections globally.

CRISPR Therapeutics is focused on the development of transformative medicines using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR/Cas9 is a revolutionary technology that allows for precise, directed changes to genomic DNA. They have licensed the foundational CRISPR/Cas9 patent estate for human therapeutic use from their scientific founder, Dr. Emmanuelle Charpentier, who co-invented the application of CRISPR/Cas9 for gene editing. CRISPR Therapeutics’ vision is to cure serious human diseases at the molecular level using CRISPR-Cas9. The company is headquartered in Basel, Switzerland and has operations in London, UK.

Bluesight addresses supply chain inefficiencies in healthcare by offering actionable analytics throughout the medication lifecycle. The company has developed a hospital inventory management platform that automates pharmacy kit processing and medication tracking, aiming to streamline the often cumbersome and error-prone manual processes associated with medication handling. By implementing automation technology, Bluesight enhances operational efficiency, improves patient safety, and increases medication visibility within hospitals. Through its suite of Medication Intelligence solutions, the company simplifies the complexities of medication management, providing healthcare professionals with the tools needed for better decision-making and risk reduction.

AVEO Oncology is a commercial-stage biopharmaceutical company headquartered in Boston, Massachusetts, focused on developing and marketing targeted therapies for cancer. Its lead product, tivozanib, marketed as FOTIVDA, is an oral, once-daily vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor used for treating renal cell carcinoma (RCC). The company has completed a Phase III trial of tivozanib and is investigating its use in combination with the immune checkpoint inhibitor Opdivo. Additionally, AVEO is developing Ficlatuzumab, an antibody targeting hepatocyte growth factor, currently in Phase II trials for several cancers, and AV-203, an anti-ErbB3 monoclonal antibody that has completed Phase I trials for esophageal cancer. The company also has preclinical products aimed at cachexia and pulmonary arterial hypertension. AVEO collaborates with various pharmaceutical companies to enhance its research and development efforts. Established in 2001, AVEO Oncology aims to address unmet medical needs in oncology through its innovative therapies.

Aptinyx Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative therapies for brain and nervous system disorders. Founded in 2015 and based in Evanston, Illinois, the company focuses on novel, synthetic small molecules that modulate the NMDA receptor, enhancing communication pathways between nerve cells. Its primary products in development include NYX-2925, which is undergoing Phase II trials for painful diabetic peripheral neuropathy and fibromyalgia, and NYX-783, currently in Phase I trials for post-traumatic stress disorder. Additionally, Aptinyx is developing NYX-458, another NMDA receptor modulator, which is in Phase I clinical studies aimed at treating cognitive impairment associated with Parkinson’s disease. The company also collaborates with Allergan to develop compounds for major depressive disorder, underscoring its commitment to addressing significant unmet medical needs in the central nervous system arena.

Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing anti-infective therapies to address multi-drug resistant pathogens. Headquartered in Dublin, Ireland, the company is advancing its lead product, sulopenem, a novel penem compound available in both oral and intravenous formulations. Currently in Phase III clinical trials, sulopenem is being evaluated for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum aims to provide effective solutions to combat antibiotic resistance, particularly against a range of gram-negative, gram-positive, and anaerobic bacteria that are resistant to existing antibiotics. Founded in 2015, Iterum Therapeutics seeks to improve the lives of patients affected by serious and life-threatening infections globally.

AiCure, LLC is a technology company that specializes in medication adherence and intelligent medical assistant solutions, utilizing a visual recognition platform to monitor patient progress via mobile devices. The company's software confirms medication ingestion, particularly in clinical trials and high-risk populations, by identifying both patients and medications while detecting issues such as diversion and duplicate enrollments. It captures evidence of medication ingestion for immediate intervention and long-term adherence tracking. AiCure's platform incorporates advanced data analytics, including patented facial recognition and motion-sensing technology, to link patient behavior with treatment outcomes. This innovative approach aims to enhance healthcare delivery systems by improving treatment efficacy and reducing risks. Founded in 2009 and based in New York, AiCure has established a strategic partnership with Syneos Health to further advance its solutions.

True North Therapeutics, Inc. is a biotechnology company focused on developing therapies that target the complement pathway of the immune system, specifically for rare diseases with high unmet clinical needs. Founded in 2013 and based in South San Francisco, California, the company’s lead product, TNT009, is a monoclonal antibody designed to selectively inhibit the classical complement pathway. This approach aims to prevent inflammatory mediators and phagocytosis in conditions such as cold agglutinin disease, warm autoimmune hemolytic anemia, and other complement-mediated disorders. True North is also exploring additional treatment options for a variety of diseases in hematology, dermatology, and neurology. The company operates as a subsidiary of Bioverativ Inc.

Arvinas, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, that specializes in the discovery, development, and commercialization of innovative therapies aimed at degrading disease-causing proteins. The company's lead product candidates include ARV-110, a proteolysis targeting chimera (PROTAC) currently in phase I clinical trials for metastatic castration-resistant prostate cancer, and ARV-471, which targets the estrogen receptor for patients with metastatic ER-positive/HER2-negative breast cancer. In addition to these, Arvinas is developing various other PROTACs aimed at degrading clinically relevant androgen receptor mutations and treatments for neurodegenerative diseases, including tauopathies. The company has established collaborations with prominent pharmaceutical firms such as Pfizer Inc., Genentech, and Bayer AG, enhancing its research capabilities and reach within the biopharmaceutical landscape. Founded in 2015, Arvinas aims to improve patient outcomes by eliminating harmful proteins from the body through its proprietary technology.

Deciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, focused on developing innovative treatments for cancer. The company aims to improve the lives of cancer patients by addressing mechanisms of drug resistance that hinder effective therapy responses. Its lead candidate, ripretinib, is specifically designed for gastrointestinal stromal tumors and is undergoing trials for various other cancers, including gliomas and melanoma. Additionally, Deciphera is advancing other clinical-stage candidates, such as DCC-3014, targeting tenosynovial giant cell tumors, and Rebastinib, which is being explored in combination with chemotherapy for solid tumors. The company also has a preclinical candidate, DCC-3116, aimed at treating RAS mutant cancers. Deciphera leverages its proprietary switch-control kinase inhibitor platform and has received regulatory approvals for its lead product in several countries, enhancing its commitment to developing vital cancer therapies.

Kyruus, Inc. is a Boston-based company that develops web-based software solutions aimed at optimizing physician networks for hospitals, health systems, and life science companies. Founded in 2010, Kyruus offers a suite of analytically driven products designed to enhance provider search and scheduling, ensuring that patients are matched with the most suitable healthcare providers. Key offerings include Kyruus Passport, which allows physicians to track their activity and productivity, and Kyruus Profiles, which enables administrators to analyze physician performance metrics. Additionally, the company provides Kyruus MDSeekyr, a platform for identifying high-value providers, and Kyruus Insight Reports, which help executives evaluate network activity and performance trends. By leveraging a proprietary provider data management platform, Kyruus enhances patient engagement and aligns provider supply with patient demand, ultimately improving the overall healthcare experience. Kyruus also maintains offices in San Francisco and New York.

ReShape Medical Inc. specializes in non-surgical weight loss solutions aimed at individuals with mild to moderate obesity, specifically those with a Body Mass Index (BMI) of 30 to 40. The company offers the ReShape Integrated Dual Balloon System, which consists of two intragastric balloons that are placed in the stomach and filled with saline. This system is intended to assist patients in losing weight when combined with a medically supervised diet and exercise program. The procedure is designed for adults who have not achieved significant weight loss through diet and exercise alone. ReShape Medical also provides other weight management solutions, including the FDA-approved Lap-Band System and the investigational ReShape Vest System, which aim to support patients in their weight loss journeys while minimizing the need for invasive surgical procedures. Founded in 2005 and based in San Clemente, California, ReShape Medical operates as a subsidiary of EnteroMedics Inc.

Wave Life Sciences Ltd. is a clinical-stage genetic medicine company focused on developing innovative RNA-based therapies. Utilizing its proprietary PRISM platform, the company designs, optimizes, and produces stereopure oligonucleotides aimed at addressing genetic defects. By targeting ribonucleic acid (RNA), Wave aims to either diminish the production of harmful proteins or convert dysfunctional proteins into functional ones. The company's primary focus is on neurology, particularly disorders affecting the central and neuromuscular systems. Wave Life Sciences has established research and collaboration agreements with major pharmaceutical companies, including Pfizer and Takeda, to further advance its therapeutic programs. Founded in 2012 and headquartered in Singapore, Wave Life Sciences is dedicated to delivering transformative treatments for patients with genetically defined diseases.

Principia Biopharma Inc. is a late-stage biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for immune-mediated diseases. The company's lead candidate, rilzabrutinib, is an inhibitor currently undergoing Phase III clinical trials for pemphigus and pemphigus foliaceus, as well as Phase 1/2 and Phase 2 trials for immune thrombocytopenia and IgG4-related disease, respectively. Additionally, Principia is advancing PRN2246/SAR442168, aimed at treating multiple sclerosis and other central nervous system disorders, which is in Phase II trials. Another candidate, PRN473, is in Phase I trials for various immune-mediated diseases. Principia Biopharma collaborates with Genzyme Corporation to explore treatments for relapsing and progressive multiple sclerosis, enhancing its commitment to addressing significant unmet medical needs in immunology and oncology. Established in 2008, the company operates as a subsidiary of Sanofi.

Afferent Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, founded in 2009. The company focuses on developing small molecule drugs aimed at treating chronic pain and various neurogenic disorders by targeting P2X3 receptors in nerve fibers. Its lead compound, AF-219, has completed two Phase 1 clinical studies and is designed to address conditions such as osteoarthritis, back pain, visceral pain, and neuropathy, as well as respiratory and urological issues.

Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at enhancing personalized medicine. Utilizing its proprietary RNAscope technology, the company offers a versatile platform for multiplex fluorescent and chromogenic in situ hybridization, allowing for the detection and quantification of RNA biomarkers with single molecule sensitivity. Its product portfolio includes manual assays, reagent kits in various formats, and software tools for quantitative analysis of RNA in situ hybridization samples. The company serves pharmaceutical and biotech sectors by providing assay services that facilitate understanding of disease mechanisms and support various stages of clinical trials. Additionally, Advanced Cell Diagnostics maintains a companion diagnostic assay development program to streamline assay processes. The company's products are distributed across numerous countries and are also available for purchase online. Founded in 2007 and located in Hayward, California, Advanced Cell Diagnostics operates as a subsidiary of Bio-Techne Corp.

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases, utilizing proprietary T-cell engineering technology alongside tumor-targeting antibodies to harness the body’s immune system in the fight against cancer. The company designs targeted treatments aimed at addressing the underlying causes of diseases, thereby improving patient outcomes. One of its key programs, CGT9486, is a selective tyrosine kinase inhibitor that specifically targets the KIT D816V mutation and other mutations in KIT exon 17. This mutation is predominantly linked to Systemic Mastocytosis, a severe condition resulting from the uncontrolled growth of mast cells, and is also associated with advanced gastrointestinal stromal tumors. Cogent Biosciences is advancing its lead program, which is expected to enter Phase I clinical trials to evaluate safety and efficacy.

Neuronetics, Inc. is a commercial-stage medical technology company based in Malvern, Pennsylvania, focused on developing non-invasive therapies for psychiatric disorders. Founded in 2003, the company markets the NeuroStar Advanced Therapy System, which provides an innovative treatment for adult patients with major depressive disorder. This system employs transcranial magnetic stimulation, utilizing pulsed, MRI-strength magnetic fields to generate electrical currents that target specific brain areas linked to mood regulation. Neuronetics sells its products primarily through a dedicated sales and customer support team, catering to psychiatrists and healthcare providers. The company aims to enhance the quality of life for individuals suffering from mental health conditions through its advanced therapeutic solutions.

Dimension Therapeutics, Inc. is a gene therapy company dedicated to developing innovative treatments for rare and metabolic diseases linked to liver function. Founded in 2013 and based in Cambridge, Massachusetts, the company has established a robust pipeline of gene therapy candidates. Its lead products include DTX101 for hemophilia B and DTX201 for hemophilia A, alongside other programs targeting conditions such as ornithine transcarbamylase deficiency, glycogen storage disease type Ia, phenylketonuria, Wilson disease, and citrullinemia type I. Dimension Therapeutics collaborates with REGENX Biosciences, leveraging its extensive patent portfolio related to NAV vector technology. This partnership enhances Dimension's ability to advance its gene therapy initiatives, particularly in the realm of adeno-associated virus therapeutics. In 2017, Dimension Therapeutics became a subsidiary of Ultragenyx Pharmaceutical Inc.

Edge Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapies for acute neurological conditions, particularly in hospital settings. Founded in 2009 and based in Berkeley Heights, New Jersey, the company aims to transform treatment paradigms for serious medical conditions with significant unmet needs. Its lead product candidate, EG-1962, is currently being evaluated in the Phase 3 NEWTON 2 study for the treatment of aneurysmal subarachnoid hemorrhage, a condition resulting from bleeding around the brain due to a ruptured aneurysm. Additionally, Edge is developing EG-1964 as a potential prophylactic treatment for chronic subdural hematoma, aiming to prevent recurrent bleeding on the brain's surface. The company employs its proprietary Precisa platform to create polymer-based therapeutics that deliver treatment directly to the site of injury, minimizing impact on surrounding tissues.

Bluesight addresses supply chain inefficiencies in healthcare by offering actionable analytics throughout the medication lifecycle. The company has developed a hospital inventory management platform that automates pharmacy kit processing and medication tracking, aiming to streamline the often cumbersome and error-prone manual processes associated with medication handling. By implementing automation technology, Bluesight enhances operational efficiency, improves patient safety, and increases medication visibility within hospitals. Through its suite of Medication Intelligence solutions, the company simplifies the complexities of medication management, providing healthcare professionals with the tools needed for better decision-making and risk reduction.

CardioKinetix, Inc., based in Menlo Park, California, specializes in developing transcatheter implants aimed at treating heart failure. The company's primary product, the Parachute Ventricular Partitioning Device, is designed to improve cardiac function in patients who have developed ischemic left-sided heart failure following a heart attack. By isolating the dysfunctional region of the heart ventricle and reducing chamber volume, the device enhances cardiac output, addressing a critical need in heart failure management. CardioKinetix serves a diverse customer base across several countries, including the United States and various European nations, and aims to provide effective treatment options for millions affected by heart failure globally. The company was incorporated in 2002.

QPID Health, Inc. is a healthcare IT software company headquartered in Boston, Massachusetts, with an additional location in San Diego, California. The company specializes in a health record intelligence platform known as the Queriable Programmable Inference Dossier (QPID), which was originally developed at Massachusetts General Hospital. This platform enables healthcare institutions and clinicians to extract valuable insights from electronic health records (EHRs) through real-time queries, analytics, and reporting capabilities at the point of care. QPID is designed to be EHR agnostic, automatically delivering context-sensitive information to enhance clinical workflows and decision-making. By utilizing advanced technologies such as natural language processing and machine learning, the platform aims to improve clinician productivity, support informed care decisions, and ultimately enhance patient outcomes while reducing costs. Founded in 2013 by Dr. Michael Zalis and Dr. Mitch Harris, QPID Health is backed by notable investors, including Matrix Partners and the Massachusetts General Physicians Organization.

Principia Biopharma Inc. is a late-stage biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for immune-mediated diseases. The company's lead candidate, rilzabrutinib, is an inhibitor currently undergoing Phase III clinical trials for pemphigus and pemphigus foliaceus, as well as Phase 1/2 and Phase 2 trials for immune thrombocytopenia and IgG4-related disease, respectively. Additionally, Principia is advancing PRN2246/SAR442168, aimed at treating multiple sclerosis and other central nervous system disorders, which is in Phase II trials. Another candidate, PRN473, is in Phase I trials for various immune-mediated diseases. Principia Biopharma collaborates with Genzyme Corporation to explore treatments for relapsing and progressive multiple sclerosis, enhancing its commitment to addressing significant unmet medical needs in immunology and oncology. Established in 2008, the company operates as a subsidiary of Sanofi.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Versartis is a biotechnology company based in Redwood City, California, focused on developing therapeutic proteins for endocrine disorders. The company specializes in recombinant human growth hormones and employs a novel half-life extension technology known as XTEN to enhance treatment efficacy. Versartis is advancing its lead program, VRS-317, which has recently completed enrollment in a multi-center Phase 1 clinical study targeting adult patients with growth hormone deficiency. The company aims to improve patient compliance and treatment outcomes by reducing the frequency of daily injections associated with traditional therapies. Founded in December 2008 through a joint venture with Amunix Inc. and Index Ventures, Versartis is supported by a team of drug development experts and leverages external contract services to efficiently execute its product development strategies.

TigerConnect is a provider of clinical communication solutions tailored for the healthcare sector, enabling effective collaboration among doctors, nurses, patients, and care providers. Founded in 2010 and headquartered in Santa Monica, California, the company offers a platform that integrates real-time mobile messaging with a user-friendly interface, while prioritizing security and privacy. Trusted by over 4,000 healthcare organizations, TigerConnect processes more than 10 million messages daily and boasts a 99.99% uptime. Its innovative products and seamless integrations with essential hospital systems enhance workflow efficiency, ultimately accelerating productivity, reducing costs, and improving patient outcomes. The company's commitment to client success is evident through its dedicated support organization, which collaborates with clients to optimize communication workflows and maximize return on investment.

Versartis is a biotechnology company based in Redwood City, California, focused on developing therapeutic proteins for endocrine disorders. The company specializes in recombinant human growth hormones and employs a novel half-life extension technology known as XTEN to enhance treatment efficacy. Versartis is advancing its lead program, VRS-317, which has recently completed enrollment in a multi-center Phase 1 clinical study targeting adult patients with growth hormone deficiency. The company aims to improve patient compliance and treatment outcomes by reducing the frequency of daily injections associated with traditional therapies. Founded in December 2008 through a joint venture with Amunix Inc. and Index Ventures, Versartis is supported by a team of drug development experts and leverages external contract services to efficiently execute its product development strategies.

Catalyst Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of therapies for rare and debilitating neuromuscular and neurological diseases in the United States. The company's primary product, Firdapse, is a proprietary formulation of amifampridine phosphate designed for treating Lambert-Eaton Myasthenic Syndrome, a rare autoimmune disorder. In addition to its approved use for this condition, Catalyst is also conducting clinical trials to explore Firdapse's efficacy for other disorders, including congenital myasthenic syndrome and certain refractory cases of myasthenia gravis. Founded in 2002 and based in Coral Gables, Florida, Catalyst Pharmaceuticals has established license agreements for the development of additional treatments, including a collaboration with Endo Ventures for generic formulations.

Karyopharm Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Newton, Massachusetts, specializing in the discovery, development, and commercialization of novel drugs targeting nuclear export mechanisms for the treatment of cancer and other diseases. Its lead drug, XPOVIO (selinexor), is an approved treatment for multiple hematologic malignancies, particularly in patients with heavily pretreated multiple myeloma. The company is advancing several clinical trials for its products, including BOSTON and STORM for multiple myeloma, SADAL for relapsed or refractory diffuse large B-cell lymphoma, and SEAL for liposarcoma. Karyopharm is also exploring treatments for endometrial cancer and glioblastoma multiforme. Additionally, the company has partnerships to investigate low-dose selinexor for hospitalized COVID-19 patients and collaborates with the National Cancer Institute for cancer therapy evaluations. Karyopharm utilizes a proprietary platform to develop small molecule drugs that modulate key cellular pathways involved in cancer and inflammation.

Versartis is a biotechnology company based in Redwood City, California, focused on developing therapeutic proteins for endocrine disorders. The company specializes in recombinant human growth hormones and employs a novel half-life extension technology known as XTEN to enhance treatment efficacy. Versartis is advancing its lead program, VRS-317, which has recently completed enrollment in a multi-center Phase 1 clinical study targeting adult patients with growth hormone deficiency. The company aims to improve patient compliance and treatment outcomes by reducing the frequency of daily injections associated with traditional therapies. Founded in December 2008 through a joint venture with Amunix Inc. and Index Ventures, Versartis is supported by a team of drug development experts and leverages external contract services to efficiently execute its product development strategies.

Bluesight addresses supply chain inefficiencies in healthcare by offering actionable analytics throughout the medication lifecycle. The company has developed a hospital inventory management platform that automates pharmacy kit processing and medication tracking, aiming to streamline the often cumbersome and error-prone manual processes associated with medication handling. By implementing automation technology, Bluesight enhances operational efficiency, improves patient safety, and increases medication visibility within hospitals. Through its suite of Medication Intelligence solutions, the company simplifies the complexities of medication management, providing healthcare professionals with the tools needed for better decision-making and risk reduction.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Treato Ltd. operates a health information platform that aggregates and analyzes patient experiences sourced from the Internet, particularly from social media sites and forums. The platform provides valuable insights for patients, healthcare professionals, pharmaceutical companies, and other healthcare organizations. By employing advanced Natural Language Processing, Treato extracts relevant information from the vast amount of patient-written health experiences, creating a comprehensive understanding of public sentiment regarding medications and health conditions. Treato also offers Treato Pharma, a specialized service that delivers real-time analytics and insights to pharmaceutical marketers, helping them interpret patient opinions, understand competitive dynamics, and enhance patient engagement. Founded in 2008 and based in Yehud, Israel, Treato serves as a critical resource for both consumers and the healthcare industry, with its advertising-free consumer site attracting hundreds of thousands of users weekly.

iRhythm Technologies is a digital healthcare company that specializes in ambulatory electrocardiogram (ECG) monitoring for patients at risk of arrhythmias in the United States. Its flagship product, the Zio service, features a wire-free, patch-based biosensor designed for comfortable wear, enabling continuous monitoring of heart activity for up to 14 days. This wearable technology is complemented by a cloud-based data analytics platform that utilizes machine learning to transform extensive heartbeat data into actionable clinical insights. iRhythm aims to enhance the early diagnosis and treatment of cardiac arrhythmias, ultimately improving patient health outcomes while reducing unnecessary healthcare costs. Established in 2006 and headquartered in San Francisco, the company also collaborates with Verily Life Sciences to develop advanced atrial fibrillation monitoring solutions.

Pearl Therapeutics is a privately held company dedicated to developing innovative therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, rhinosinusitis, and asthma. The company specializes in creating unique dual and triple combination products, focusing on advanced inhaled therapies that are delivered through familiar metered dose inhalers. Led by a team of experienced professionals in respiratory product development, Pearl Therapeutics aims to provide patients and healthcare providers with alternatives that better address their needs. The company's goal is to enhance the safety and efficacy of existing respiratory treatments, ultimately improving clinical outcomes for individuals suffering from these conditions.

CardioKinetix, Inc., based in Menlo Park, California, specializes in developing transcatheter implants aimed at treating heart failure. The company's primary product, the Parachute Ventricular Partitioning Device, is designed to improve cardiac function in patients who have developed ischemic left-sided heart failure following a heart attack. By isolating the dysfunctional region of the heart ventricle and reducing chamber volume, the device enhances cardiac output, addressing a critical need in heart failure management. CardioKinetix serves a diverse customer base across several countries, including the United States and various European nations, and aims to provide effective treatment options for millions affected by heart failure globally. The company was incorporated in 2002.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Versartis is a biotechnology company based in Redwood City, California, focused on developing therapeutic proteins for endocrine disorders. The company specializes in recombinant human growth hormones and employs a novel half-life extension technology known as XTEN to enhance treatment efficacy. Versartis is advancing its lead program, VRS-317, which has recently completed enrollment in a multi-center Phase 1 clinical study targeting adult patients with growth hormone deficiency. The company aims to improve patient compliance and treatment outcomes by reducing the frequency of daily injections associated with traditional therapies. Founded in December 2008 through a joint venture with Amunix Inc. and Index Ventures, Versartis is supported by a team of drug development experts and leverages external contract services to efficiently execute its product development strategies.

GluMetrics, Inc. is a medical device company based in Irvine, California, founded in 2005. It specializes in developing tools for clinicians to improve the care of critically ill patients. The company's primary product, GluCath, is an intravascular continuous glucose monitoring system designed to measure blood sugar levels in hospitalized patients. By providing real-time glucose data, GluMetrics aims to enhance patient management and outcomes in critical care settings.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Intarcia Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for chronic conditions requiring long-term treatment. The company is known for its innovative drug delivery platform, DUROS, which stabilizes and administers therapeutic proteins and peptides effectively. Among its key products is ITCA 650, currently in phase 3 clinical trials for type 2 diabetes, designed to provide patients with continuous dosing of an incretin mimetic therapy. Intarcia also explores treatments for obesity and other chronic disorders. Established in 1995 and headquartered in Boston, Massachusetts, Intarcia operates a manufacturing facility in Hayward, California, and a research and development center in Durham, North Carolina. The company was previously known as BioMedicines, Inc. before adopting its current name in 2004.

Pearl Therapeutics is a privately held company dedicated to developing innovative therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, rhinosinusitis, and asthma. The company specializes in creating unique dual and triple combination products, focusing on advanced inhaled therapies that are delivered through familiar metered dose inhalers. Led by a team of experienced professionals in respiratory product development, Pearl Therapeutics aims to provide patients and healthcare providers with alternatives that better address their needs. The company's goal is to enhance the safety and efficacy of existing respiratory treatments, ultimately improving clinical outcomes for individuals suffering from these conditions.

MEI Pharma, Inc. is a late-stage pharmaceutical company based in San Diego, California, dedicated to developing innovative therapies for cancer treatment. The company's clinical pipeline includes several key drug candidates such as Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor currently in Phase II trials for relapsed follicular lymphoma, and Voruciclib, an oral cyclin-dependent kinase inhibitor under investigation for acute myeloid leukemia and B-cell malignancies in Phase Ib trials. Additionally, MEI Pharma is developing ME-344, a mitochondrial inhibitor targeting HER2-negative breast cancer, and Pracinostat, an oral histone deacetylase inhibitor being tested for myelodysplastic syndrome. The company has established various collaborations and agreements with notable partners, including Kyowa Kirin Company and BeiGene, to support its clinical development efforts. Founded in 2000, MEI Pharma has evolved significantly since its inception and continues to focus on advancing its promising oncology therapies.

Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at enhancing personalized medicine. Utilizing its proprietary RNAscope technology, the company offers a versatile platform for multiplex fluorescent and chromogenic in situ hybridization, allowing for the detection and quantification of RNA biomarkers with single molecule sensitivity. Its product portfolio includes manual assays, reagent kits in various formats, and software tools for quantitative analysis of RNA in situ hybridization samples. The company serves pharmaceutical and biotech sectors by providing assay services that facilitate understanding of disease mechanisms and support various stages of clinical trials. Additionally, Advanced Cell Diagnostics maintains a companion diagnostic assay development program to streamline assay processes. The company's products are distributed across numerous countries and are also available for purchase online. Founded in 2007 and located in Hayward, California, Advanced Cell Diagnostics operates as a subsidiary of Bio-Techne Corp.

Principia Biopharma Inc. is a late-stage biopharmaceutical company based in South San Francisco, California, focused on developing innovative therapies for immune-mediated diseases. The company's lead candidate, rilzabrutinib, is an inhibitor currently undergoing Phase III clinical trials for pemphigus and pemphigus foliaceus, as well as Phase 1/2 and Phase 2 trials for immune thrombocytopenia and IgG4-related disease, respectively. Additionally, Principia is advancing PRN2246/SAR442168, aimed at treating multiple sclerosis and other central nervous system disorders, which is in Phase II trials. Another candidate, PRN473, is in Phase I trials for various immune-mediated diseases. Principia Biopharma collaborates with Genzyme Corporation to explore treatments for relapsing and progressive multiple sclerosis, enhancing its commitment to addressing significant unmet medical needs in immunology and oncology. Established in 2008, the company operates as a subsidiary of Sanofi.

ReShape Medical Inc. specializes in non-surgical weight loss solutions aimed at individuals with mild to moderate obesity, specifically those with a Body Mass Index (BMI) of 30 to 40. The company offers the ReShape Integrated Dual Balloon System, which consists of two intragastric balloons that are placed in the stomach and filled with saline. This system is intended to assist patients in losing weight when combined with a medically supervised diet and exercise program. The procedure is designed for adults who have not achieved significant weight loss through diet and exercise alone. ReShape Medical also provides other weight management solutions, including the FDA-approved Lap-Band System and the investigational ReShape Vest System, which aim to support patients in their weight loss journeys while minimizing the need for invasive surgical procedures. Founded in 2005 and based in San Clemente, California, ReShape Medical operates as a subsidiary of EnteroMedics Inc.

Access Closure, Inc. is a medical device company based in Mountain View, California, specializing in vascular closure solutions for interventional and diagnostic procedures. Founded in 2002, the company offers innovative products, including the Mynx delivery system. This device effectively seals arteriotomy sites using a water-soluble and extravascular sealant, which expands within the tissue by absorbing blood and subcutaneous fluids. Access Closure aims to simplify and enhance the process of vascular closure, addressing the complexities associated with these medical procedures.

Relypsa, Inc. is a biopharmaceutical company based in Redwood City, California, specializing in the development and commercialization of late-stage medicines for conditions primarily in the iron deficiency, nephrology, and cardio-renal therapeutic areas. The company is known for its product VELTASSA, a potassium binder designed to treat hyperkalemia. Relypsa focuses on discovering and developing non-absorbed polymeric drugs that address cardiovascular and renal diseases, particularly conditions that are often overlooked or undertreated. Established in 2007, Relypsa operates as a subsidiary of Vifor Pharma Ltd.

Pearl Therapeutics is a privately held company dedicated to developing innovative therapies for prevalent respiratory diseases, including chronic obstructive pulmonary disease, rhinosinusitis, and asthma. The company specializes in creating unique dual and triple combination products, focusing on advanced inhaled therapies that are delivered through familiar metered dose inhalers. Led by a team of experienced professionals in respiratory product development, Pearl Therapeutics aims to provide patients and healthcare providers with alternatives that better address their needs. The company's goal is to enhance the safety and efficacy of existing respiratory treatments, ultimately improving clinical outcomes for individuals suffering from these conditions.

Presidio Pharmaceuticals, Inc. is a specialty pharmaceutical company based in San Francisco, California, dedicated to the discovery and development of small-molecule antiviral therapeutics. Founded in 2006, the company primarily focuses on creating therapies for viral infections, with a significant emphasis on hepatitis C virus (HCV) and HIV. Its product portfolio features pan-genotypic HCV NS5A inhibitors and ravidasvir hydrochloride, which target the NS5A and NS5B proteins of HCV. Presidio's antiviral therapeutics are designed for daily oral dosing and can be combined with other antiviral classes to address viral resistance, thus providing patients with effective treatment options against various hepatitis genotypes. The company has raised over $27 million from several investors to support its research and development efforts.

IlluminOss Medical, Inc. is a commercial-stage medical device company that specializes in minimally invasive technology for fracture repair and stabilization. The company has developed a unique system that uses a light-curable polymer within an expandable balloon to create a patient-conforming intramedullary implant, facilitating effective bone stabilization. This innovative approach is particularly beneficial for patients with osteoporotic or compromised bone, providing a tailored solution for orthopedic challenges. The IlluminOss system is CE-marked and FDA-cleared for various anatomical sites, with additional indications under review. By focusing on the design and marketing of orthopedic fracture repair products, IlluminOss aims to offer clinicians a rapid and customized method for stabilizing bone fractures.